|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sung JJ, Lau JY, Goh KL and Leung WKAsia
Pacific Working Group on Colorectal Cancer: Increasing incidence of
colorectal cancer in Asia: Implications for screening. Lancet
Oncol. 6:871–876. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lu J, Getz G, Miska EA, et al: MicroRNA
expression profiles classify human cancers. Nature. 435:834–838.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Manikandan J, Aarthi JJ, Kumar SD and
Pushparaj PN: Oncomirs: The potential role of non-coding microRNAs
in understanding cancer. Bioinformation. 2:330–334. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Meltzer PS: Cancer genomics: Small RNAs
with big impacts. Nature. 435:745–746. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fang K, Qian F and Chen YQ: MicroRNAs as
regulators in normal hematopoietic and leukemia stem cells: Current
concepts and clinical implications. Curr Mol Med. 12:536–546. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Saito Y, Liang G, Egger G, et al: Specific
activation of microRNA-127 with downregulation of the
proto-oncogene BCL6 by chromatin-modifying drugs in human cancer
cells. Cancer Cell. 9:435–443. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lujambio A, Ropero S, Ballestar E, et al:
Genetic unmasking of an epigenetically silenced microRNA in human
cancer cells. Cancer Res. 67:1424–1429. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Suzuki H, Yamamoto E, Nojima M, et al:
Methylation-associated silencing of microRNA-34b/c in gastric
cancer and its involvement in an epigenetic field defect.
Carcinogenesis. 31:2066–2073. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Toyota M, Suzuki H, Sasaki Y, et al:
Epigenetic silencing of microRNA-34b/c and B-cell translocation
gene 4 is associated with CpG island methylation in colorectal
cancer. Cancer Res. 68:4123–4132. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Koutsoulidou A, Mastroyiannopoulos NP,
Furling D, Uney JB and Phylactou LA: Expression of miR-1, miR-133a,
miR-133b and miR-206 increases during development of human skeletal
muscle. BMC Dev Biol. 11:342011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu J, Yang T, Li X, et al: Alteration of
serum miR-206 and miR-133b is associated with lung carcinogenesis
induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Toxicol
Appl Pharmacol. 267:238–246. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yamamoto H, Kohashi K, Fujita A and Oda Y:
Fascin-1 overexpression and miR-133b downregulation in the
progression of gastrointestinal stromal tumor. Mod Pathol.
26:563–571. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao H, Li M, Li L, Yang X, Lan G and
Zhang Y: MiR-133b is down-regulated in human osteosarcoma and
inhibits osteosarcoma cells proliferation, migration and invasion
and promotes apoptosis. PLoS One. 8:e835712013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Crawford M, Batte K, Yu L, et al: MicroRNA
133B targets pro-survival molecules MCL-1 and BCL2L2 in lung
cancer. Biochem Biophys Res Commun. 388:483–489. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Patron JP, Fendler A, Bild M, et al:
MiR-133b targets antiapoptotic genes and enhances death
receptor-induced apoptosis. PLoS One. 7:e353452012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hu G, Chen D, Li X, Yang K, Wang H and Wu
W: miR-133b regulates the MET proto-oncogene and inhibits the
growth of colorectal cancer cells in vitro and in vivo. Cancer Biol
Ther. 10:190–197. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xiang KM and Li XR: MiR-133b acts as a
tumor suppressor and negatively regulates TBPL1 in colorectal
cancer cells. Asian Pac J Cancer Prev. 15:3767–3772. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
General Assembly of the World Medical
Association, . World Medical Association Declaration of Helsinki:
Ethical principles for medical research involving human subjects. J
Am Coll Dent. 81:14–18. 2014.PubMed/NCBI
|
|
23
|
Izutsu N, Maesawa C, Shibazaki M, et al:
Epigenetic modification is involved in aberrant expression of class
III beta-tubulin, TUBB3, in ovarian cancer cells. Int J Oncol.
32:1227–1235. 2008.PubMed/NCBI
|
|
24
|
Bandrés E, Cubedo E, Agirre X, et al:
Identification by Real-time PCR of 13 mature microRNAs
differentially expressed in colorectal cancer and non-tumoral
tissues. Mol Cancer. 5:292006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ogasawara S, Maesawa C, Yamamoto M, et al:
Disruption of cell-type-specific methylation at the Maspin gene
promoter is frequently involved in undifferentiated thyroid
cancers. Oncogene. 23:1117–1124. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Karpinski P, Szmida E, Misiak B, et al:
Assessment of three epigenotypes in colorectal cancer by combined
bisulfite restriction analysis. Mol Carcinog. 51:1003–1008. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xiang T, Li L, Yin X, et al: The ubiquitin
peptidase UCHL1 induces G0/G1 cell cycle arrest and apoptosis
through stabilizing p53 and is frequently silenced in breast
cancer. PLoS One. 7:e297832012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Saito Y, Friedman JM, Chihara Y, Egger G,
Chuang JC and Liang G: Epigenetic therapy upregulates the tumor
suppressor microRNA-126 and its host gene EGFL7 in human cancer
cells. Biochem Biophys Res Commun. 379:726–731. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Saito Y, Suzuki H, Tsugawa H, et al:
Chromatin remodeling at Alu repeats by epigenetic treatment
activates silenced microRNA-512-5p with downregulation of Mcl-1 in
human gastric cancer cells. Oncogene. 28:2738–2744. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Duan FT, Qian F, Fang K, et al: miR-133b,
a muscle-specific microRNA, is a novel prognostic marker that
participates in the progression of human colorectal cancer via
regulation of CXCR4 expression. Mol Cancer. 12:1642013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wen D, Li S, Ji F, et al: miR-133b acts as
a tumor suppressor and negatively regulates FGFR1 in gastric
cancer. Tumour Biol. 34:793–803. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhou Y, Wu D, Tao J, Qu P, Zhou Z and Hou
J: MicroRNA-133 inhibits cell proliferation, migration and invasion
by targeting epidermal growth factor receptor and its downstream
effector proteins in bladder cancer. Scand J Urol. 47:423–432.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu L, Shao X, Gao W, Zhang Z, Liu P, Wang
R, Huang P, Yin Y and Shu Y: MicroRNA-133b inhibits the growth of
non-small-cell lung cancer by targeting the epidermal growth factor
receptor. FEBS J. 279:3800–3812. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tao J, Wu D, Xu B, Qian W, Li P, Lu Q, Yin
C and Zhang W: microRNA-133 inhibits cell proliferation, migration
and invasion in prostate cancer cells by targeting the epidermal
growth factor receptor. Oncol Rep. 27:1967–1975. 2012.PubMed/NCBI
|
